As new therapies emerge, particularly for non-muscle invasive disease, clinicians and patients are faced with increasingly ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

First-line treatment for advanced urothelial carcinoma has evolved in recent years from traditional chemotherapy to targeted immunotherapy drugs enfortumab vedotin (Padcev) and pembrolizumab (Keytruda ...

Explore surgical options for metastatic bladder cancer, including radical cystectomy and metastasectomy. Learn how surgery can improve survival and quality of life.

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for ...

(Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...